Clinical Trial Update: Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pirfenidone (Esbriet) for pulmonary fibrosis associated with coal workers' pneumoconiosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coal Workers Pneumoconiosis
• Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Sponsor: Pulmonary Research of Abingdon, LLC | Conditions: Coal Workers' Pneumoconiosis (Complicated) | Phase 2 | Status: COMPLETED